Pemetrexed + Carboplatin + demcizumab
Phase 2Completed 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Nonsquamous Nonsmall Cell Neoplasm of Lung
Conditions
Nonsquamous Nonsmall Cell Neoplasm of Lung
Trial Timeline
Feb 1, 2015 → Apr 7, 2017
NCT ID
NCT02259582About Pemetrexed + Carboplatin + demcizumab
Pemetrexed + Carboplatin + demcizumab is a phase 2 stage product being developed by Mereo BioPharma for Nonsquamous Nonsmall Cell Neoplasm of Lung. The current trial status is completed. This product is registered under clinical trial identifier NCT02259582. Target conditions include Nonsquamous Nonsmall Cell Neoplasm of Lung.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02259582 | Phase 2 | Completed |
Competing Products
7 competing products in Nonsquamous Nonsmall Cell Neoplasm of Lung
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Pemetrexed + Erlotinib + Pemetrexed + Erlotinib | Eli Lilly | Phase 2 | 52 |
| Patritumab Deruxtecan + Platinum-based chemotherapy | Daiichi Sankyo | Phase 3 | 77 |
| Pembrolizumab + Carboplatin + Cisplatin + Pemetrexed + Lenvatinib + Placebo matching lenvatinib | Eisai | Phase 3 | 77 |
| Pembrolizumab + Carboplatin + Cisplatin + Pemetrexed + Lenvatinib + Placebo matching lenvatinib | Eisai | Phase 3 | 77 |
| Pemetrexed | Eli Lilly | Phase 2 | 52 |
| Pembrolizumab + Pemetrexed + Carboplatin + Cisplatin + Olaparib | Merck | Phase 3 | 77 |
| Erlotinib | Roche | Pre-clinical | 23 |